Pathogenic variants in THSD4, encoding the ADAMTS-like 6 protein, predispose to inherited thoracic aortic aneurysm by Elbitar, Sandy et al.
Pathogenic variants in THSD4, encoding the ADAMTS-like 6
protein, predispose to inherited thoracic aortic aneurysm
Sandy Elbitar, PharmD, PhD1,2, Marjolijn Renard, PhD3, Pauline Arnaud, PharmD, PhD1,4,5,
Nadine Hanna, PharmD, PhD1,4,5, Marie-Paule Jacob, PhD1, Dong-Chuan Guo, PhD6, Ko Tsutsui, PhD7,
Marie-Sylvie Gross, MS1, Ketty Kessler, PhD8, Laurent Tosolini, MS1, Vincenzo Dattilo, PhD9,
Sebastien Dupont, PhD1, Jeremie Jonquet, MS1, Maud Langeois, MS5, Louise Benarroch, PhD1,10,
Melodie Aubart, MD, PhD1,11, Youmna Ghaleb, PharmD, PhD1,2, Yara Abou Khalil, PharmD1,2,
Mathilde Varret, PhD1, Petra El Khoury, PharmD, PhD1,2, Benoit Ho-Tin-Noé, PhD1,
Yves Alembik, MD12, Sébastien Gaertner, MD13, Bertrand Isidor, MD14, Laurent Gouya, MD, PhD5,
Olivier Milleron, MD5, Kiyotoshi Sekiguchi, PhD7, Dianna Milewicz, MD, PhD6,
Julie De Backer, MD, PhD3, Carine Le Goff, PhD1, Jean-Baptiste Michel, MD, PhD1,
Guillaume Jondeau, MD, PhD1,5, Lynn Y. Sakai, PhD15, Catherine Boileau, PharmD, PhD1,4,5 and
Marianne Abifadel, PharmD, PhD 1,2
Purpose: Thoracic aortic aneurysm and dissection (TAAD) is a
life-threatening disease with often unrecognized inherited forms.
We sought to identify novel pathogenic variants associated with
autosomal dominant inheritance of TAAD.
Methods:We analyzed exome sequencing data from 35 French TAAD
families and performed next-generation sequencing capture panel of
genes in 1114 unrelated TAAD patients. Functional effects of pathogenic
variants identified were validated in cell, tissue, and mouse models.
Results: We identified five functional variants in THSD4 of which two
heterozygous variants lead to a premature termination codon. THSD4
encodes ADAMTSL6 (member of the ADAMTS/L superfamily), a
microfibril-associated protein that promotes fibrillin-1 matrix assembly.
The THSD4 variants studied lead to haploinsufficiency or impaired
assembly of fibrillin-1 microfibrils. Thsd4+/- mice showed progressive
dilation of the thoracic aorta. Histologic examination of aortic samples
from a patient carrying a THSD4 variant and from Thsd4+/- mice,
revealed typical medial degeneration and diffuse disruption of extra-
cellular matrix.
Conclusion: These findings highlight the role of ADAMTSL6 in aortic
physiology and TAAD pathogenesis. They will improve TAAD
management and help develop new targeted therapies.
Genetics in Medicine (2020) https://doi.org/10.1038/s41436-020-00947-4
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INTRODUCTION
Thoracic aortic aneurysm leading to aortic rupture or
dissection (TAAD) is an asymptomatic, life-threatening
disease, with 50% mortality prior to arrival to hospital and
~40% 30-day mortality for those admitted to hospital.1 In
patients with TAAD, dilation of the arterial wall associated
with a progressive loss of its ability to withstand the wall
tension generated by high intraluminal pressure can lead to
intramural or complete acute vessel wall rupture.2 Surgical
treatment remains the main intervention to prevent
dissections.3
While TAAD can occur in the context of syndromes,
including Marfan syndrome (MFS; MIM 154700),
Loeys–Dietz syndrome (MIM 609192, 608967, 610168, and
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610380) and aneurysms–osteoarthritis syndrome (MIM
613795), many cases are nonsyndromic. Importantly, up to
20% of individuals who experience nonsyndromic TAAD
have a family history of TAAD (hTAAD, for heritable
TAAD),2,4–6 suggesting that familial screening for genetic
causes of TAAD could help identify individuals at risk for
developing this condition.
Many genes have been identified that are associated with
hTAAD. Alterations in these genes define three separate
pathogenic mechanisms affecting the aortic wall: alteration of
an extracellular matrix (ECM) component (such as fibrillin-17
encoded by FBN1, or MAGP2 encoded by MFAP58),
alteration of TGFβ signaling (TGFBR1,9 TGFBR2,10 or
TGFB211), or alteration of smooth muscle cell (SMC)
contraction (MYH11 encoding smooth muscle myosin heavy
chain 11, or ACTA2 encoding smooth muscle α actin),
metabolism or migration.12 HTAAD shows high clinical
variability and low, as well as incomplete, penetrance. It tends
to present in older patients, as highlighted by age-related
onset of disease in almost all hTAAD family lineages.
Furthermore, women tend to develop aortic manifestations
at more advanced ages compared with men.13,14
To date, pathogenic variants in known genes account for less
than 20% of hTAAD cases, suggesting that the genetic
heterogeneity of this disorder is even greater than is currently
understood.6,15 Given the importance of genetic screening for
individuals at risk of developing hTAAD and the high
proportion of cases of TAAD with unknown causes, we sought
to identify novel genetic pathogenic variants associated with
this condition. Here, we report five functional variants in the
THSD4 (thrombospondin, type I, domain containing 4) gene
in hTAAD families and probands with TAAD. THSD4 encodes
ADAMTSL6, a microfibril-associated protein that binds
directly to fibrillin-1 and promotes fibrillin-1 matrix assem-
bly.16 It belongs to the ADAMTS/L superfamily, which
comprises 19 secreted enzymes (ADAMTS, for A disintegrin
and metalloproteinase with thrombospondin motifs) and seven
secreted glycoproteins (ADAMTSL, for ADAMTS-like).17 The
ADAMTS are extracellular metalloproteinases that are
involved in ECM turnover. Members of the ADAMTSL
subfamily are homologous to ADAMTS proteins, but do not
have enzyme activity, as they lack the superfamily’s consensus
catalytic domain.16,18 Several studies conducted in mouse
models of aortic dilation have recently reported that
ADAMTS/L family members play a role in aortopathies, and
their effects are often detected or enhanced by angiotensin II
infusion.19–21 Members of this family would be interesting
candidate genes in hTAAD. Our genetic approach links
ADAMTSL6 to hTAAD. In vitro functional studies of the
ADAMTSL6 variants confirmed their altered function. Histo-
logic examination of aortic samples revealed diffuse disruption
of the media. Furthermore, investigation of a Thsd4+/- mouse
model showed pathogenic effects on the thoracic aorta. Thus,
human genetic studies together with functional studies and a
mouse model suggest that ADAMTSL6 is a new player in
aortic physiology and pathology.
MATERIALS AND METHODS
Ethics statement
All patients gave their written informed consent for
participation in this study in agreement with the requirements
of French bioethics laws (institutional review board [IRB]
approval from the Comité de Protection des Personnes [CPP]
Ile de France XI, 78105 St Germain en Laye, registration
number 11008).
Patients
Probands and families were recruited from the Centre
National Maladies Rares–Syndrome de Marfan et apparentés,
the French National Reference Centre located at Bichat
Hospital (Paris, France) and through competence centers
nationwide. Genomic DNA was isolated from peripheral
blood leukocytes by standard procedures as previously
reported.8,11,15 In total, 1114 French probands were screened
for diagnosis of possible syndromic (notably MFS) or
nonsyndromic TAAD through a multidisciplinary clinical
assessment process including systematic slit-lamp examina-
tion, extensive imaging (including aortic echocardiography),
and molecular analysis.
Exome sequencing
It was performed on 106 patients from 35 TAAD-affected
families in which no causal variant in genes previously
associated with TAAD had been identified (consecutive to
Sanger sequencing or next-generation sequencing capture
panel of candidate genes). DNA samples from affected
members of TAAD families were sequenced by Integragen
S.A. (Evry, France), as previously reported.8,11
DNA amplification and variant detection
Genomic DNA was sheared into fragments ranging from
200–300 bp using a Bioruptor ultrasonicator (Diagenode,
Seraing, Belgium). A custom capture array (NimbleGen
SeqCap®, Roche) was designed and used to capture all coding
exons, splice sites, and the flanking intron sequences of
THSD4 gene (NM_024817) and 23 other genes already known
to be associated with Marfan syndrome and associated disease
and heritable thoracic aneurysm and dissections. Amplifica-
tion, sequencing, and variant annotation were performed as
previously described.8,11,15 All variants of interest were
systematically confirmed by bidirectional Sanger sequencing
primers (in Supplementary table S1).
Additional details concerning materials and methods are
found in the Supplementary Information.
RESULTS
Next-generation sequencing allowed the identification of
TAAD-associated genetic variants
To identify the genetic causes of TAAD in a French cohort,
we performed sequencing of 1114 unrelated patients with a
clinical spectrum ranging from syndromic to nonsyndromic
TAAD. We also analyzed exome sequencing data from 35
French hTAAD families, investigating novel or rare variants
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(minor allele frequency [MAF] <0.1% in non-Finnish
European populations, according to gnomAD). Overall,
we found a likely pathogenic variant (class 4 and 5 according
to American College of Medical Genetics and Genomics–
Association for Molecular Pathology [ACMG-AMP] recom-
mendation) in ~30% of the cases, a class 3 variant (VUS) in
~5% of the cases, and in ~65% of the cases, no interesting
potential pathogenic variant was identified in previously
identified genes. In the context of identifying new genes
associated to TAAD, we pinpointed 22 variants in a new
candidate gene, THSD4, that encodes ADAMTSL6, an ECM
protein known to promote fibrillin-1 matrix assembly (Fig. 1a,
Table 1, and Supplementary table S2). THSD4 is composed of
17 coding exons, with two transcript variants encoding two
isoforms of 1018 and 658 amino acids, respectively (Fig. 1b).
Five of the 22 variants were found in probands for whom
family members were available for segregation analysis (Fig. 1a
and Table 1) and thus were further investigated.
Two heterozygous variants were found in two probands.
Both variants resulted in a premature termination codon
(PTC) and have not been previously reported in population
databases. The male proband (II.6) of the first family (TAA-
1889; Fig. 1a and Table 1) suffered from type A aortic
dissection at the age of 43. The aortic diameter prior to
dissection was unknown. He exhibited a mild pectus
excavatum, dolichostenomelia, and a high-arched palate. He
was not known to have arterial hypertension. He carried the
c.740del variant, a deletion of one of the three consecutive
thymines at position 738, leading to the p.(Leu247*) PTC
variant. His mother (I.2), operated on for ascending aortic
dissection at the age of 75 years (aortic diameter unknown),
also carried the variant. The proband’s two sons (III.5 and
III.6), aged 24 and 25 years, respectively, did not present
dilated aortas upon echocardiography and did not carry the
variant. Finally, the proband’s brother (II.2; 61 years) did not
carry the variant, and had a normal aortic root diameter but
mild dilation of the ascending tubular aorta, with a history of
arterial hypertension.
The second PTC variant was found in a family (TAA-1839;
Fig. 1a and Table 1). The molecular event is a single-
nucleotide deletion in a three-guanine repeat at position 1400
(c.1402del) that leads to a PTC (p.[Ala468Glnfs*45]). The
variant was identified in the female proband (II.2) and her
daughter (III.3). Both displayed dilation of the ascending
aorta, with diameters of 42 mm at the aortic root and 47 mm
at ascending aorta for the mother and 28 mm at the aortic
root and 32 mm at the ascending aorta for the daughter. The
proband’s sister (II.3) (aortic root: 33 mm, ascending aorta:
36 mm) also carried the variant. The proband’s mother (I.2)
had a normal aortic root diameter (37 mm) at the age of 75
years, and did not carry the variant. The proband inherited
the variant from her father (I.1), for whom there is no
evidence of the disease, and can constitute a case of
incomplete penetrance, especially because exome sequencing
performed in this family did not allow identification of any
other possible gene variant linked to the disease.
Furthermore, a 9-bp in-phase duplication that has not been
previously reported in population databases was identified in
a third family (TAA-1850; Fig. 1a, Table 1). The
c.137_145dup duplication is expected to lead to p.
(Asp46_Gly48dup). Aortic root dilation (48 mm) was dis-
covered in the proband (II.3) after myocardial infarction at
the age of 39 years. He suffered from high blood pressure and
hypercholesterolemia, and was an active smoker. He has three
children (III.1, III.2, and III.3) without aortic dilation and
who did not carry the duplication. His brother (II.4), who
carried the duplication, was operated on for aortic dissection
at the age of 42 years, and dilation of the ascending aorta was
present prior to dissection. Finally, the proband’s father (I.1),
who carried the duplication, was operated on for aortic
dilation of the ascending aorta and abdominal aorta at the age
of 68 years.
Two heterozygous missense variants were identified in the
series of unrelated probands tested: substitutions in exon 5
(c.961T>A; p.[Tyr321Asn]) and in exon 13 (c.2341C>T; p.
[Arg781Trp]). The tyrosine substitution was found in a
female proband who underwent Bentall surgery for aortic
regurgitation at the age of 61 years. Her daughter was the only
other family member available for study. The daughter had an
aortic root diameter of 30 mm and ascending aorta diameter
of 29 mm at the age of 25 years, and carried the variant. This
variant has not been previously reported in population
databases. It was predicted by PolyPhen-2 to be probably
damaging, by SIFT to be deleterious, and by the CADD
algorithm to be among the top 1% of the most deleterious
substitutions possible in the human genome (score of 29.1).
The p.(Arg781Trp) variant was found in a proband who had
elective surgery for an aortic root diameter of 50 mm at 57
years old. His brother, who does not carry the variant, is alive
at the age of 84 years, with no evidence of a thoracic aortic
disease. This variant is rare with a reported frequency of
0.000035 in gnomAD European non-Finnish database
(rs767807136). It was predicted to be probably damaging by
PolyPhen-2, to be deleterious by SIFT, and to have a CADD
score of 21.0, indicating that it is in the top 1% of most
deleterious substitutions possible in the human genome.
We selected a sixth variant from among 17 other rare
variants (frequency <0.1% in the gnomAD European non-
Finnish database) identified by sequencing the THSD4 gene in
the unrelated probands with TAAD (Supplementary table S2).
This variant, p.(Gly753Asp) (c.2258G>A), was found in three
unrelated TAAD probands. Although this variant was also
found in gnomAD controls, its frequency is low (0.00035 [45/
128,528] in the gnomAD European Non-Finnish database).
Furthermore, it affects a CpG doublet, which is known to be
highly mutable. We therefore hypothesized that this could
represent either a founder pathogenic variant or a variant
hotspot for this disease and we included this variant in our
functional studies. The locations of these six variants with
respect to the gene and the protein are shown in Fig. 1b. It
should be noted that three of the variants affect both the type
1 and type 2 isoforms of ADAMTSL6.
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NP_001273358.1 encoded by
NM_001286429.1
SP: Signal Peptide
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b
Fig. 1 THSD4 functional variant segregation in families with a history of thoracic aortic aneurysms. (a) Segregation of THSD4 variants p.
(Leu247*), p.(Ala468Glnfs*45), and p.(Asp46_Gly48dup) with symptoms of cardiac disease respectively in families TAA-1889, TAA-1839, TAA-1850 with a
history of thoracic aortic aneurysm and dissection (TAAD). Black arrows indicate probands. (b) Schematic representation of the THSD4 gene and protein
indicating the location of pathogenic variants identified in French families. THSD4 is composed of 17 coding exons. Two premature termination codon (PTC)
variants were identified in two families: c.740del in exon 4 leading to p.(Leu247*) and c.1402del in exon 8 leading to p.(Ala468Glnfs*45). The variant p.
(Asp46_Gly48dup) was identified in a third family. Functional studies were performed for the following missense variants: p.(Tyr321Asn), p.(Gly753Asp),
and p.(Arg781Trp). Reference transcript variants 1 and 2 are shown: variant 1 (NM_024817.2) represents the longer transcript and encodes the longer
isoform (NP_079093.2). Variant 2 (NM_001286429.1) differs in the 5’ UTR and lacks multiple 5’ coding exons, compared with variant 1. It represents use of
an alternate promoter and initiates translation from an alternate start codon. The encoded isoform 2 (NP_001273358.1) has a distinct N-terminus and is
shorter than isoform 1.
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PTC and missense variants in THSD4 lead to
haploinsufficiency or impaired assembly of fibrillin-1
microfibrils
We next sought to investigate the functional effect of the
DNA variants identified as described above. For the PTC
variants, THSD4 messenger RNA (mRNA) expression was
tested in cultured skin fibroblasts from four patients with and
without emetine, which prevents nonsense-mediated mRNA
decay (NMD). Basal expression varied greatly between
individuals, even between patients carrying the same THSD4
variation, and this effect was not related to age (Fig. 2a).
THSD4 expression was significantly increased in the presence
of emetine, demonstrating NMD both for the p.(Leu247*)
variant in patient (II.6) from the TAA-1889 family and the p.
(Ala468Glnfs*45) variant in patients (III.3, II.2, and I.1) from
the TAA-1839 family (Fig. 2a). Thus, the functional effects of
these PTC variants could be explained by haploinsufficiency.
However, to determine the effects of the three THSD4
missense variants, MG-63 cells were transiently transfected
with wild-type (WT) or mutated constructs, knowing that
ADAMTSL6 is an ECM protein that promotes fibrillin-1
microfibrils assembly in those cells. When cells were
transfected with the WT construct, an extensive and well-
organized fibrillin-1-positive microfibril array formed in five
days compared with empty vector (Fig. 2b,c). In contrast, cells
transfected with the THSD4-Arg781Trp or THSD4-
Tyr321Asn constructs exhibited very few fibrillin-1–positive
microfibrils (Fig. 2d,e). In cells transfected with the THSD4-
Gly753Asp construct, few islands of fibrillin-1–positive
microfibrils were found; but in general, only punctate
nonorganized structures were observed (Fig. 2f). Semiquanti-
tative analysis of the images obtained from the immunocy-
tochemistry analysis showed that there was a significant
decrease in the signal obtained with the THSD4-Arg781Trp
and THSD4-Tyr321Asn constructs compared with WT
(Fig. 2g), which confirmed the qualitative observations. Cells
transfected with the THSD4-Gly753Asp construct exhibited a
strong cell staining of fibrillin-1 compared with WT. Taken
together, these findings suggest that missense variants in
THSD4 lead to impaired assembly of fibrillin-1 microfibrils
(Fig. 2, Supplementary Fig. S1).
THSD4 variant is associated with disorganization of the
aortic media
The human aortic pathology associated with THSD4 patho-
genic variants was assessed using the only available patient’s
aortic tissue, i.e., from the 48-year-old female proband
carrying the THSD4 p.(Ala468Glnfs*45) PTC variant. Aortic
tissue from a female patient carrying the p.(Cys2307Arg)
variant in the FBN1 gene, one of the major genes in hTAAD,
was used as reference for the aortic histology of hTAAD and
compared with normal ascending aorta tissue from a healthy
control. Pathology typical of thoracic aortic disease was found
in both patients, including disorganization of the media with
fragmentation and disarray of elastic fibers, accumulation of
proteoglycans, and areas of medial degeneration along with
SMC rarefaction (Fig. 3a–c). TGFβ1 enrichment was
observed, particularly around microvessels, compared with
normal aorta (Fig. 3d), highlighting the angiogenic process
associated with TAAD.22 Aneurysmal tissues showed an
increase in nuclear phosphorylated SMAD2/3 levels in the
most affected part of the medial layer that did not colocalize
with TGFβ1 (Fig. 3e), as previously reported.23 Fibrillin-1 was
almost undetectable in healthy aortic tissue (Fig. 3f),
presumably because of poor immunoavailability due to its
tight incorporation within hydrophobic elastic fibers.24,25 It
was organized in aggregates that accumulated parallel to
elastic fibers and exhibited a pericellular signal in aortic tissue
from variants carriers (Fig. 3f). In agreement with previous
results,26 fibronectin seemed to be more abundant in
aneurysmal tissues compared with healthy aorta (Fig. 3g).
Aortic sections from the FBN1 p.(Cys2307Arg) and THSD4 p.
(Ala468Glnfs*45) carriers showed condensed pericellular
fibronectin aggregated around SMCs (Fig. 3g). These findings
showed medial degeneration with diffuse disruption of ECM
and activation of TGF-β pathway associated with the THSD4
PTC variant.
Thsd4+/- mice present progressive thoracic aortic dilation
To confirm observations found in human aortas and to
identify the role of ADAMTSL6 encoded by THSD4 in aortic
dilation, a mouse model was generated. Thsd4+/- mice had a
normal lifespan. Vascular echography analysis was performed
to assess thoracic aortic diameters in WT and Thsd4+/- mice
at different ages (3–12 months). We observed a significant
increase in aortic diameter in the Thsd4+/- mice (P < 1.10−4 at
6, 8, and 12 months) compared with WT (Fig. 4a). The aortic
diameters significantly increased with time (sinus of Valsalva
P < 1.10−4; ascending aorta P < 1.10−4; arch P < 1.10−3;
descending aorta P < 1.10−2) in both WT and Thsd4+/- mice
(Fig. 4b). A statistically significant interaction between
genotype and time was observed at the sinus of Valsalva
(P= 0.01), arch (P= 0.02), and descending aorta (P < 1.10−3).
This interaction demonstrated that aortic diameter in
Thsd4+/- mice increased more with time than in WT mice.
To test whether there are differences between aortic tissue
from WT and Thsd4+/- mice, we performed histochemical
analysis. Young Thsd4+/- mice (0–5 months) do not seem to
have a defect in elastic fiber formation. The aortas of Thsd4+/-
mice at 6 and 9 months showed patchy accumulation of
Alcian Blue–positive areas, revealing the presence of proteo-
glycans, unlike those of a 6-month-old WT mouse (Fig. 4c).
This observation was confirmed by a more pronounced
disorganization of autofluorescent elastin in Thsd4+/- com-
pared with WT mice (Fig. 4d). The nuclei of Thsd4+/- mice
exhibited a more significant degree of DNA degradation
compared with WT mice at 6 months of age, as indicated by
the ratio of TUNEL-positive to Dapi-positive nuclei (Fig. 4e).
Interestingly, visualization of nuclei in the same area of an
aorta tissue sample taken from a 9-month-old Thsd4+/-
mouse by three different methods, revealed that, while some
nuclei were predominantly positive for hematoxylin staining
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(tinctorial), they were negative for Dapi staining (double
strand DNA marker) but positive for TUNEL staining
(degraded DNA marker) (Fig. 4f). This suggests that there
is a decrease in the number of SMC nuclei present in the 9-
month-old Thsd4+/- mouse, implying a loss of SMC tissue in
the Thsd4+/- mice as they age. Therefore, accumulation of
proteoglycans with disorganization of elastic fibers in the
ECM along with SMC alteration were observed in the
Thsd4+/- mice, and could explain the aortic dilation observed
in these mice as they age compared with WT.
DISCUSSION
In this study, we identified loss-of-function pathogenic
variants in the THSD4 gene encoding ADAMTSL6 as a novel
mechanism underlying inherited thoracic aortic aneurysm in
humans. THSD4 encodes ADAMTSL6, a microfibril-
associated protein known to bind directly to fibrillin-1 and
to promote fibrillin-1 matrix assembly.16 We showed that
PTC and missense variants in THSD4 lead to haploinsuffi-
ciency of ADAMTSL6 and/or impaired assembly of fibrillin-1
microfibrils. Furthermore, the observed correlation of these
variants with the disease in patients was confirmed by a
Thsd4+/- mouse model that showed progressive aortic dilation
at the level of the thoracic aorta that increased significantly
over time compared with control mice. All these data in
patients and mice support that THSD4 is a novel protagonist
in the pathophysiology of hTAAD and confirm the role of
ADAMTSL6 in microfibril formation and homeostasis.16
ADAMTSL6 is one of the ADAMTSL proteins, a subgroup
of the ADAMTS superfamily.16 ADAMTS-1, ADAMTS-4,
and ADAMTS-5 are proteoglycanases that cleave large
hyaluronan-binding proteoglycans in the vasculature.27,28
Pathogenic variants in ADAMTSL proteins have been
implicated in two human genetic diseases: bone geleophysic
dysplasia for ADAMTSL229 and autosomal recessive familial
ectopia lentis for ADAMTSL4.30 No ADAMTS/L variants
have previously been associated with thoracic aortic disease in
humans except a single recent report31 of a patient with
geleophysic dysplasia carrying a pathogenic variant in
ADAMTSL2.29 At 48 years of age, this is the oldest patient
ever reported presenting with the disease. Interestingly, along
with typical skeletal features, the patient displayed a severely
regurgitant aortic valve that was surgically replaced, with a
dilation of the ascending aorta and the main pulmonary
artery. Since the mean life expectancy for these patients is in
the third decade, it is possible that the aortic pathology of this
autosomal recessive form of the disease appears only at
midlife and thus had never been observed before this case. In
keeping with this hypothesis, all of the probands carrying
THSD4 variants assessed in this study were diagnosed with
TAAD in midlife. Therefore, pathogenic variants in these two
genes can be associated with a later onset TAAD.
Even though the exact function of ADAMTSL2 remains
incompletely elucidated, it is known to interact directly with
the C-terminal and the N-terminal half of fibrillin-132 and to
partner with TGFβ binding protein 1.17,29,33–35 In human as
well as in mouse, ADAMTSL6 is known to promote
microfibril assembly and in mouse it binds to the N-
terminal half of fibrillin-1.16,36 This could confirm that
ADAMTSL2 and ADAMTSL6 play physiological roles in
the development and maintenance of the aortic ECM as well
as pathological processes, like fibrillin-1 and TGFβ signaling,
also known to be altered in hTAAD.31,37,38 Indeed, histolo-
gical analysis of mouse and human aortic tissues showed that
THSD4 variants led to the same medial degeneration as
observed with pathogenic variants within the FBN1 gene as
well as in several genes encoding proteins of TGFβ
metabolism and signaling pathway.16,36 Furthermore, pericel-
lular fibronectin aggregated around SMCs was also observed.
Fibronectin acts not only as a general orchestrator of matrix
assembly, but is also a matrix stabilizer since it is essential for
maintenance of cell–matrix adhesion sites.32 Fibronectin
fibrillogenesis is typically pericellular, involves interactions
with the cell surface and clustering of α5β1 integrins, and has
been shown to be a prerequisite of microfibril formation,39
interacting with the C-terminus of fibrillin-1.40 In keeping
with these data, it could be speculated that haploinsufficiency
for ADAMTSL6 in the aortic wall alters microfibrillar
homeostasis, triggering a healing process that initiates
through fibronectin production and fibrillogenesis but that
is stalled at the stage of pericellular fibrillin-1-rich microfibril
assembly. Therefore, the signals of altered homeostasis are
maintained and could explain the abundance of pericellular
fibronectin observed in the aortic tissue obtained from the
Fig. 2 Missense variants in THSD4 lead to haploinsufficiency or impaired assembly of fibrillin-1 microfibrils. (a) Evaluation of nonsense-mediated
messenger RNA (mRNA) decay (NMD) in skin fibroblasts from THSD4 premature termination codon (PTC) variants carriers. Skin fibroblasts were obtained from
the proband (II.6) carrying the p.(Leu247*) variant in TAA-1889 and patients (III.3, II.2, and I.1) carrying the p.(Ala468Glnfs*45) variant from family TAA-1839.
Fibroblasts from individual I.2 from family TAA-1839 were used as the control. Fibroblasts were grown with or without emetine (an inhibitor of the NMD
pathway). Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was performed to evaluate the basal level of expression of THSD4 in those
conditions. RT-qPCR data are presented as means ± standard error of the mean (n= 6 for variant carriers, n= 3 for control, experiment repeated on two
independent cell cultures). Statistical differences were analyzed using a two-tailed Mann–Whitney test (*P < 0.05; **P < 0.01; ***P < 0.001). (b–f) Immu-
nocytochemistry of fibrillin-1 (red) was performed in MG-63 cells transfected with empty vector (b) or vectors encoding wild-type (WT) ADAMTSL6 (c) or the
different mutated forms (p.[Arg781Trp] [d], p.[Tyr321Asn] [e] and p.(Gly753Asp) [f]) 5 days after plating. Images are representative of three independent
experiments. Scale bar for (a–e), 20 µm. (g) A semiquantitative assay was performed using fibrillin-1 staining normalized to the nuclear surface, in images
obtained from the immunocytochemistry analysis 5 days after plating. Results are expressed as means of normalized fibrillin-1 staining ± standard error of the
mean of 25 images per condition (WT was analyzed in duplicate). The dashed line indicates the mean level of fibrillin-1 staining normalized to surface of
nuclei, obtained with empty vector. Statistical differences were analyzed using a two-tailed Mann–Whitney test (*P < 0.05; ***P < 0.001).
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patient carrying the THSD4 p.(Ala468Glnfs*45) PTC variant.
The presence in the same location of microfibrils could also
reveal a role of ADAMTSL6 in promoting higher level
organization of the microfibrillar network. Thus, Thsd4
haploinsufficiency may lead to improper orchestration and
orientation of microfibril assembly. Further studies are
needed to test this hypothesis and notably a possible
interaction of ADAMTSL6 and fibronectin.
Another typical aspect of TAAD aortic pathology observed
in a patient’s samples was the presence of TGFβ in the media
and the presence of pSmad2/3 in SMC nuclei. Adamtsl6
directly binds TGFβ, and administration of
Adamtsl6 suppresses nuclear localization of pSmad2/3 in
transgenic Fbn1 mgR/mgR mice.36 Therefore, the higher
TGFβ signal observed for the THSD4 variant carrier may be
related to the lack of available ADAMTSL6 in the aortic wall.
Our findings confirm that increased expression of THSD4
promotes the assembly of fibrillin-1 microfibrils and show
that missense variants lead to their impaired assembly. This
observation is in accordance with previous results showing
that fibrillin-1 matrix assembly was promoted in the early but
not the late stage of the assembly process when cells were
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Fig. 3 A pathogenic premature termination codon (PTC) variant in THSD4 is associated with medial degeneration and activation of the TGFβ
pathway. (a–c) Histology of aortic media from the 48-year-old TAA-1839 proband (II:2), carrying the THSD4 p.(Ala468Glnfs*45) variant (middle) compared
with a 54-year-old thoracic aortic aneurysm (TAA) female patient carrying the FBN1 p.(Cys2307Arg) variant (right) along with normal ascending aorta
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features of medial degeneration: disorganization of the media with fragmented and disordered elastic fibers, accumulation of proteoglycans and smooth
muscle cell (SMC) rarefaction in the individuals with the THSD4 and FBN1 variants. Scale bar, 25 µm. (d) Immunohistochemical analysis of the same tissues
showed increased TGFβ1 expression, particularly around microvessels, in aortic tissue from the THSD4 and FBN1 variant carriers compared with normal
aorta. Scale bar, 50 µm. (e) Aneurysmal tissue from individuals carrying THSD4 and FBN1 variants show a diffuse increase in nuclear pSmad2/3 expression in
the most affected medial layer compared with control aortic tissue. Scale bar, 50 µm. (f) Immunofluorescent (red) fibrillin-1 is almost undetectable in healthy
aorta. It appears as discontinuous, aggregated microfibrils parallel to elastic fibers in aortic tissue from the patients carrying the FBN1 p.(Cys2307Arg) and
THSD4 p.(Ala468Glnfs*45) variants. Scale bar, 10 µm. (g) Fibronectin appears to be overexpressed in aneurysmal tissues compared with healthy aorta. The
aneurysmal aortic sections showed condensed, pericellular fibronectin staining with some aggregates appearing around SMCs. Scale bar, 10 µm. Elastic
fibers appear in green in (f, g) (autofluorescence).
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transfected or exogenously supplemented with ADAMTSL6.16
It has also been shown that expression of Adamtsl6 rescues
microfibril disorder after periodontal ligament injury in a
MFS mouse model.36 Thus, ADAMTSL6 might constitute a
new therapeutic target in TAAD, a group of diseases that still
lacks targeted treatment other than appropriate prevention of
its life-threatening complications.
Despite the limitations of this study, such as small TAA
pedigrees of a complex inherited disorder known for its
multifactorial genetic and environmental risk factors, the
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availability of just one sample for histological studies in
human, and the analysis of only male heterozygous deficient
mice, our work reveals that heterozygous variants in THSD4,
encoding ADAMTSL6, play a role in thoracic aortic disease in
human. The observed/expected (o/e) score of THSD4, which
is the recommended indicator of loss-of-function intolerance
in gnomAD, is 0.39 (confidence interval [CI]: 0.28–0.57),
indicating that this gene could play a role in human disease.
On the other hand, through the study of 1114 probands and
35 families with a clinical spectrum ranging from syndromic
to nonsyndromic TAAD from a French cohort, we found
~35% of class 4/5 and class 3 variants. This is higher than the
28% previously reported in a French nonsyndromic heritable
TAAD cohort15 but can be explained by the presence in our
study of syndromic patients. Furthermore, despite the
tremendous development in sequencing techniques, ~65% of
the cases remain negative in our collection and that of others.6
Therefore, these negative cases constitute a groundwork for
other research projects aiming to identify novel genes in
hTAAD, of which few are currently under consideration and
could be validated in the future.
In conclusion, our findings suggest that pathogenic variants
in THSD4 lead to inherited TAAD. This contributes to a
better understanding of the pathophysiology of the disease, its
genetic diagnosis, prevention, and eventually its treatment.
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